Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/13/2026

Initial Antihypertensive Medication Selection for Hypertension Treatment

Treatment Algorithm Based on Blood Pressure Severity

  • For patients with blood pressure 140-159/90-99 mmHg, the American Heart Association recommends starting with a single antihypertensive agent from one of the four major drug classes, with selection based on patient characteristics and comorbidities 1, 2
  • For patients with diabetes, chronic kidney disease, or high cardiovascular risk, the American College of Cardiology recommends initiating pharmacological treatment immediately 2, 3
  • For low-risk patients, the American Heart Association suggests considering a trial of lifestyle modifications for 3-6 months before starting medication 2

Medication Selection Based on Patient Demographics

  • For non-Black patients, the American Heart Association recommends initial therapy with an ACE inhibitor or ARB, such as lisinopril 10 mg daily or losartan 50 mg daily 2
  • For Black patients, the American College of Cardiology recommends initial therapy with a calcium channel blocker or thiazide-like diuretic 2, 4

Specific Comorbidity Considerations

  • For patients with albuminuria or chronic kidney disease, the American Diabetes Association recommends first choice as ACE inhibitor or ARB, with target dose of lisinopril 20-40 mg daily or losartan 50-100 mg daily 1, 3
  • For patients with heart failure, the American College of Cardiology recommends first choice as ACE inhibitor, such as lisinopril starting at 5 mg daily, with a diuretic, and adding beta-blockers for patients with reduced ejection fraction 3
  • For patients with coronary artery disease, the American Heart Association recommends first choice as ACE inhibitor or ARB, and considering adding beta-blockers for those with prior myocardial infarction 3, 5
  • For patients with diabetes, the American Diabetes Association recommends first choice as ACE inhibitor or ARB, and adding a calcium channel blocker or thiazide-like diuretic if blood pressure goal not achieved 1, 3

Step-wise Treatment Approach

  • The American Heart Association recommends starting with one medication at a low dose, and increasing the dose or adding a second agent if blood pressure goal not achieved after 4 weeks 2, 4
  • For resistant hypertension, the American College of Cardiology recommends using triple therapy with ACE inhibitor/ARB + calcium channel blocker + thiazide-like diuretic, and adding a mineralocorticoid receptor antagonist like spironolactone if necessary 1, 2, 3, 5

Evidence-Based Medication Selection

  • Single-pill combinations improve medication adherence, according to the American Heart Association 2, 5

Common Pitfalls to Avoid

  • The American College of Cardiology recommends avoiding combination of ACE inhibitors with ARBs due to increased risk of adverse effects without additional benefit 1, 3
  • The American Heart Association recommends avoiding use of beta-blockers as first-line therapy unless specifically indicated, such as coronary artery disease or heart failure 5
  • The American Diabetes Association recommends not delaying initiation of drug therapy in high-risk patients or those with blood pressure ≥160/100 mmHg 1, 2

Treatment Targets

  • For most adults, the American Heart Association recommends target blood pressure <130/80 mmHg 3
  • For elderly patients (≥65 years), the American College of Cardiology recommends individualizing targets based on frailty, with systolic blood pressure goal of 130-139 mmHg if tolerated 5
  • The American Heart Association recommends aiming to achieve target blood pressure within 3 months of initiating therapy 2, 4

Evidence‑Based Management of Hypertension in Primary Care

Treatment Initiation Thresholds

Blood Pressure Targets

First‑Line Drug Selection and Compelling Indications

Escalation and Resistant Hypertension

Contraindications and Safety Monitoring

Baseline Evaluation Prior to Therapy

Follow‑Up and Monitoring

Adjunctive Cardiovascular Risk Reduction